FDA Clearance Tracker · P240039-S001
SetPoint System
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 16, 2026
Approved
Time to decision
142 days
Received Aug 27, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240039-S001
- Device name
- SetPoint System
- Applicant
- SetPoint Medical
- Applicant location
- Valencia, CA
- Received
- Aug 27, 2025
- Decided
- Jan 16, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240039
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
The SetPoint System is indicated for use in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs).
Source documents
Other decisions for SetPoint Medical
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SetPoint SystemBreakthroughPMA
P240039 · Decided Jul 30, 2025 · 268 days after receipt
Device type: Vagus nerve stimulator for rheumatoid arthritis (SFJ) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.